Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Carcinoma, Renal Cell 45Carcinoma, Hepatocellular 13Osteosarcoma 8Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Sarcoma, Ewing 6Neuroendocrine Tumors 6Kidney Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Transitional Cell 4Carcinoma, Medullary 4Carcinoma 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Thyroid Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Adrenocortical Carcinoma 3Wilms Tumor 2Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2

Interventions

pembrolizumab 2relacorilant 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1cabozantinib 1Specimen Handling 1Mesna 1Magnetic Resonance Spectroscopy 1Floxuridine 1Dexamethasone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Cortex Neoplasms × cabozantinib × 1 year × Clear all
NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡